In fact, its expression occurs in 1/5 of glioblastoma (GBM) patients and is suggestive of worst prognosis for those with grade III gliomas; interestingly, 92.3% of BTK-positive patients’ samples show also co-expression of EGFR and p53 (indicative of mutated p53). Here, BTK is linked to glioblastoma.